Apolipoprotein B and non-HDL cholesterol are more powerful predictors for incident type 2 diabetes than fasting glucose or glycated hemoglobin in subjects with normal glucose tolerance: a 3.3-year retrospective longitudinal study

You-Cheol Hwang; Hong-Yup Ahn; Sung-Woo Park; Cheol-Young Park

doi:10.1007/s00592-014-0587-x

journal article May 11, 2014

Apolipoprotein B and non-HDL cholesterol are more powerful predictors for incident type 2 diabetes than fasting glucose or glycated hemoglobin in subjects with normal glucose tolerance: a 3.3-year retrospective longitudinal study

You-Cheol Hwang Hong-Yup Ahn Sung-Woo Park

Cheol-Young Park

Acta Diabetologica Vol. 51 No. 6 pp. 941-946 · Springer Science and Business Media LLC

View at Publisher Save 10.1007/s00592-014-0587-x

Topics

No keywords indexed for this article. Browse by subject →

References

19

[1]

Adiels M, Olofsson SO, Taskinen MR, Borén J (2008) Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 28:1225–1236 10.1161/atvbaha.107.160192

[2]

Bamba V, Rader DJ (2007) Obesity and atherogenic dyslipidemia. Gastroenterology 132:2181–2190 10.1053/j.gastro.2007.03.056

[3]

Barter PJ (2011) The causes and consequences of low levels of high-density lipoproteins in patients with diabetes. Diabetes Metab J 35:101–106 10.4093/dmj.2011.35.2.101

[4]

Sniderman AD, Furberg CD, Keech A et al (2003) Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 361:777–780 10.1016/s0140-6736(03)12663-3

[5]

Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment

John J.P. Kastelein, Wim A. van der Steeg, Ingar Holme et al.

Circulation 2008 10.1161/circulationaha.107.713438

[6]

Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E (2001) High apolipoprotein B, low apolipoprotein A-I and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358:2026–2033 10.1016/s0140-6736(01)07098-2

[7]

Thompson A, Danesh J (2006) Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies. J Intern Med 259:481–492 10.1111/j.1365-2796.2006.01644.x

[8]

Ley SH, Harris SB, Connelly PW et al (2010) Association of apolipoprotein B with incident type 2 diabetes in an aboriginal Canadian population. Clin Chem 56:666–670 10.1373/clinchem.2009.136994

[9]

Salomaa V, Havulinna A, Saarela O et al (2010) Thirty-one novel biomarkers as predictors for clinically incident diabetes. PLoS ONE 5:e10100 10.1371/journal.pone.0010100

[10]

Hwang YC, Ahn HY, Yu SH, Park SW, Park CY (2014) Atherogenic dyslipidaemic profiles associated with the development of Type 2 diabetes: a 3.1-year longitudinal study. Diabet Med 31:24–30 10.1111/dme.12278

[11]

Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)

Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults

JAMA 10.1001/jama.285.19.2486

[12]

Diagnosis and Classification of Diabetes Mellitus

Diabetes Care 2010 10.2337/dc10-s062

[13]

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

D. R. Matthews, J. P. Hosker, A. S. Rudenski et al.

Diabetologia 1985 10.1007/bf00280883

[14]

Binnert C, Genoud M, Seematter G et al (2005) Glucose-induced insulin secretion in dyslipidemic and normolipidemic patients with normal glucose tolerance. Diabetes Care 28:1225–1227 10.2337/diacare.28.5.1225

[15]

Laakso M, Sarlund H, Mykkänen L (1990) Insulin resistance is associated with lipid and lipoprotein abnormalities in subjects with varying degrees of glucose tolerance. Arteriosclerosis 10:223–231 10.1161/01.atv.10.2.223

[16]

Chahil TJ, Ginsberg HN (2006) Diabetic dyslipidemia. Endocrinol Metab Clin North Am 35:491–510 10.1016/j.ecl.2006.06.002

[17]

Samuel VT, Petersen KF, Shulman GI (2010) Lipid-induced insulin resistance: unravelling the mechanism. Lancet 375:2267–2277 10.1016/s0140-6736(10)60408-4

[18]

Meigs JB, Nathan DM, Wilson PW, Cupples LA, Singer DE (1998) Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance. The Framingham Offspring Study. Ann Intern Med 128:524–533 10.7326/0003-4819-128-7-199804010-00002

[19]

Preiss D, Seshasai SR, Welsh P et al (2011) Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 305:2556–2564 10.1001/jama.2011.860

Metrics

36

Citations

19

References

Details

Published: May 11, 2014
Vol/Issue: 51(6)
Pages: 941-946
License: View

Authors

Lung Biology Center and; Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Kyeonggi-Do 420-020, Korea; and

C

Cheol-Young Park

Cite This Article

You-Cheol Hwang, Hong-Yup Ahn, Sung-Woo Park, et al. (2014). Apolipoprotein B and non-HDL cholesterol are more powerful predictors for incident type 2 diabetes than fasting glucose or glycated hemoglobin in subjects with normal glucose tolerance: a 3.3-year retrospective longitudinal study. Acta Diabetologica, 51(6), 941-946. https://doi.org/10.1007/s00592-014-0587-x

Apolipoprotein B and non-HDL cholesterol are more powerful predictors for incident type 2 diabetes than fasting glucose or glycated hemoglobin in subjects with normal glucose tolerance: a 3.3-year retrospective longitudinal study

You May Also Like